A wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding.

APP Heparin products benefit from designed product packaging and labels, which help in preventing medical errors by helping physicians and clinicians deliver the proper dose to the right patient.. APP receives FDA marketing clearance for preservative-free Heparin Lock Flush Solution APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc. , announced today that it has received clearance from the U.S. Food and Medication Administration to advertise preservative-free of charge Heparin Lock Flush Alternative, USP in two dosage strengths, 10 USP Devices/1 mL and 100 USP Devices/1 mL, and can launch these single dose vial presentations soon.

Researchers first identified EV-D68 in 1962, but this past year was the first major outbreak of the virus. Most kids were vulnerable to the bug because their immune systems experienced never been exposed to it, so they never had a chance to develop immunity against the bug, Mertz said. The first cases of the virus began appearing in mid-August, and the outbreak lasted through October, according to the study authors and the CDC. The CDC documented about 1,150 cases, nearly all in children. However, the company estimates there have been likely an incredible number of mild EV-D68 infections that people didn’t seek medical care.Researchers first identified EV-D68 in 1962, but this past year was the first major outbreak of the virus. Most kids were vulnerable to the bug because their immune systems experienced never been exposed to it, so they never had a chance to develop immunity against the bug, Mertz said. The first cases of the virus began appearing in mid-August, and the outbreak lasted through October, according to the study authors and the CDC. The CDC documented about 1,150 cases, nearly all in children. However, the company estimates there have been likely an incredible number of mild EV-D68 infections that people didn’t seek medical care.